title: IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
abstract: Recent studies indicate that the cytokine B-cell activating factor (BAFF) is involved in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is standard treatment for CIDP and is known to rapidly modulate increased serum levels of pro-inflammatory cytokines. We evaluated the expression profile of BAFF and its corresponding BAFF-receptor in samples from CIDP patients, focusing on rapid changes before and after IVIg treatment. In CIDP patients BAFF serum concentrations were elevated compared to controls. Treatment with high-dose IVIg restored those elevated BAFF serum levels. Whereas treatment with IVIg did not affect BAFF production in monocytes, antibodies against BAFF could be detected in IVIg preparations, which may explain the short-term decrease of BAFF levels after IVIg treatment. Our data suggest that BAFF plays an important role in the pathogenesis of CIDP and may serve as marker for IVIg treatment response.
authors.affiliation: Dept. of Neurology and Center of Molecular Medicine Cologne, University of Cologne, Kerpenerstr. 62, D-50937 Cologne, Germany; Institut for Neuroscience und Medicin (INM-3), Forschungszentrum Jülich, Wilhelm-Johnen-Str., D-52428 Jülich, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Ritter
authors.affiliation: Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, D-40225 Düsseldorf, Germany.
authors.forename: Dominik
authors.initials: D
authors.lastname: Förster
authors.affiliation: Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, D-40225 Düsseldorf, Germany.
authors.forename: Philipp
authors.initials: P
authors.lastname: Albrecht
authors.affiliation: Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, D-40225 Düsseldorf, Germany.
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Hartung
authors.affiliation: Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, D-40225 Düsseldorf, Germany.
authors.forename: Bernd C
authors.initials: BC
authors.lastname: Kieseier
authors.affiliation: Dept. of Neurology and Center of Molecular Medicine Cologne, University of Cologne, Kerpenerstr. 62, D-50937 Cologne, Germany. Electronic address: helmar.lehmann@uk-koeln.de.
authors.forename: Helmar C
authors.initials: HC
authors.lastname: Lehmann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D053264:B-Cell Activating Factor / Q000097:blood / Q000276:immunology*; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000276:immunology*; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000097:blood / Q000276:immunology
chemical_list: D001323:Autoantibodies; D053264:B-Cell Activating Factor; D016756:Immunoglobulins, Intravenous; C114631:TNFSF13 protein, human; C505719:TNFSF13B protein, human; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13
keywords: B-cell activating factor; CIDP; Cytokine; Immune neuropathy; Therapy; Treatment